DENND2B

Across TCGA pan-cancer cohorts, DENND2B mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated DENND2B data layer compared with 21 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher DENND2B mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated DENND2B expression acts as an unfavorable survival marker, although some lineages such as HNSC and CCRCC show a favorable association.

LSCC, UCEC, and HNSC are the cancer types where DENND2B mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Median	All	0.567	0.855	<.001	51	view →
UCEC	OS	Tertile	II,III,IV	0.597	1.000	.032	8	view →
HNSC	DFS	Median	IV	1.000	0.413	.033	8	view →
CCRCC	OS	Quartile	III,IV	0.950	0.415	.002	8	view →
GBM	DFS	Median	All	0.630	0.799	.014	6	view →
LUAD	DFS	Quartile	All	0.563	0.891	.043	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

DENND2B–LSCC (DFS)

Open the LSCC breakdown →